e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 10, 2007
Micrus Endovascular Corporation
(Exact name of registrant as specified in its charter)
000-51323
(Commission File Number)
| |
|
|
| Delaware
|
|
23-2853441 |
(State or other jurisdiction of
incorporation)
|
|
(IRS Employer
Identification No.) |
821 Fox Lane
San Jose, CA 95131
(Address of principal executive offices with zip code)
(408) 433-1400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition.
On May 10, 2007, Micrus Endovascular Corporation (“Micrus”) issued a press release, reporting
its financial results for the fiscal year ended March 31, 2007. A copy of this earnings release is
attached as Exhibit 99.1 hereto. Following the issuance of this earnings release, Micrus hosted an
earnings call in which its financial results for the fiscal year ended March 31, 2007 were
discussed.
Exhibit 99.1 contains forward-looking statements within the meaning of the federal securities
laws. These statements are present expectations, and are subject to the limitations listed therein
and in Micrus’ other SEC reports, including that actual events or results may differ materially
from those in the forward-looking statements.
The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02
Results of Operations and Financial Condition” (including the exhibit hereto) and shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit |
|
Description |
99.1
|
|
Press Release dated May 10, 2007. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
MICRUS ENDOVASCULAR CORPORATION
(Registrant)
|
|
| Date: May 10, 2007 |
By: |
/s/ Robert A. Stern
|
|
| |
|
Robert A. Stern |
|
| |
|
Executive Vice President, Chief Financial Officer,
and Secretary |
|
EXHIBIT INDEX
| |
|
|
| Exhibit |
|
Description |
99.1
|
|
Press Release dated May 10, 2007 |